Family 1

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

Retrieved on: 
Tuesday, March 28, 2023
Psilocybin, Intellectual property, CSE, Depression, Drug development, MSET, Pharmacokinetics, DSM-IV codes, FSE, Research, LSD, Thermoregulation, Development, Patient, Family II, Contract research organization, Drug discovery, Family 1, Therapy, IND, Family, Pharmacology, Safety, Management, Pharmaceutical industry, Mindset

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • Mindset entered 2023 with a robust pipeline of novel psychedelic-inspired drug candidates advancing towards first-in-human clinical trials.
  • Mindset is planning to initiate human trials of its novel and patentable prodrug of psilocin, MSP-1014, shortly.
  • In light of the success of its psychedelic therapeutic programs, Mindset is shifting its drug discovery efforts in a new complementary direction.

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Retrieved on: 
Thursday, February 2, 2023
Treatment, Mindset, FSE, CNS, Family 1, United States Patent and Trademark Office, Patent, Family, CSE, MSET, Pharmaceutical industry

“We are pleased to announce that Mindset has received yet another allowance from the USPTO.

Key Points: 
  • “We are pleased to announce that Mindset has received yet another allowance from the USPTO.
  • This marks Mindset’s fourth allowance of composition of matter intellectual property (IP) rights for our growing IP portfolio,” said James Lanthier, CEO of Mindset Pharma.
  • “Now, our Family 1 is covered by 3 patent allowances, further enhancing the strategic positioning of Family 1 and reaffirming its commercial potential.”
    Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies.
  • This application is one of a family of applications having a priority date of February 4, 2020.

Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates

Retrieved on: 
Friday, January 20, 2023
Patent, Psilocybin, CSE, United States Patent and Trademark Office, FSE, CNS, Mindset, Treatment, Intellectual property, MSET, Therapy, Patient, IP, Family 1, Pharmaceutical industry

MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies.

Key Points: 
  • MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies.
  • Also included in this patent application are multiple other tryptamine prodrug candidates and other psilocybin analogs.
  • This application is one of a family of applications having a priority date of February 4, 2020.
  • Our early and consistent focus on novelty has created a valuable intellectual property (IP) portfolio,” said James Lanthier, CEO of Mindset Pharma.

Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders

Retrieved on: 
Wednesday, November 30, 2022
Well, Psilocybin, Scientific Advice Mechanism, Science, MDMA, Organization, Pharmacology, Otsuka Pharmaceutical, Health care, IND, Partnership, Patient, FSE, Major depressive disorder, Tryptamine, CGMP, Family 1, Thermoregulation, Half-life, CNS, Patent, Depression, Agreement, CSO, Research, Development, CSE, Clinical trial, MSET, DMT, CDMO, Drug discovery, Contract research organization, Safety, MDD, Management, Pharmaceutical industry, MDXX, Family, Mindset

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • Mindset is focused on a singular goal to bring best-in-class optimized psychedelic medications to patients in need.
  • Mindset has an unmatched track record of strategically partnering with organizations that can help us advance and commercialize our innovations.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014

Retrieved on: 
Wednesday, September 14, 2022
Cyclothymia, Safety, Development, Family, FSE, MDD, CTA, Company, Otsuka Pharmaceutical, Review, Patient, Clinical trial, CEO, CSE, CRO, Family 1, MHRA, Contract research organization, Scientific Advice Mechanism, GLOBE, Health care, Drug discovery, MSET, Pharmaceutical industry, Mindset

The MHRA has agreed with the Companys position and confirmed that, subject to CTA review, MSP-1014 will not require additional preclinical studies at this time.

Key Points: 
  • The MHRA has agreed with the Companys position and confirmed that, subject to CTA review, MSP-1014 will not require additional preclinical studies at this time.
  • The MHRA has also provided specific valuable guidance on potential clinical trial design regarding dosing, patient selection criteria, and safety endpoints.
  • Given its differentiation and improved pharmacological profile, Mindset prioritized moving MSP-1014 to first-in-human clinical studies.
  • We are thrilled to have received this favorable written guidance from the MHRA, confirming the readiness of MSP-1014 for Phase 1 first-in-human clinical development.

Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries

Retrieved on: 
Wednesday, September 7, 2022
CEO, CSE, Safety, Psilocybin, MSET, USPTO, FSE, Family 1, Otsuka Pharmaceutical, GLOBE, Company, Family, IP, Drug discovery, Intellectual property, Development, Patient, Pharmaceutical industry, Mindset

MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies.

Key Points: 
  • MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies.
  • Mindset filed national applications in 16 different countries altogether, including the principal South East Asian markets.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

Retrieved on: 
Tuesday, August 9, 2022
CFOS, GLOBE, Cmax, BDNF, Addiction, Brain, Patent, Board, Center, Research, Ōtsuka, Pharmacology, Patient, AUC, Board of directors, Overalls, Lists of diseases, FSE, Industry, CNS, Technology, Psychiatry, United States Patent and Trademark Office, DMT, Partnership, CAMH, Safety, CSO, Otsuka Pharmaceutical, Contract research organization, CSE, Family 1, Family II, Drug discovery, Growth, Glycoside hydrolase family 4, NCE, Drug development, Mental health, Centre for Addiction and Mental Health, Health care, Invention, MSET, RATS, IP, Psilocybin, Review, Drug design, Therapy, Central nervous system, Treatment, USPTO, Pharmaceutical industry, Fine chemical, Development, Mindset

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.

Key Points: 
  • TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset.
  • The development of this proprietary formulation technology is yet another excellent example of the dedication and scientific innovation engine from the Mindset team.
  • At Mindset, we also understand the immense value of strategic scientific and business partnerships with industry leading experts.
  • Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014

Retrieved on: 
Thursday, May 12, 2022
Catalog, Lists of diseases, Company, Contract research organization, FIH, Patient, Otsuka Pharmaceutical, Psilocybin, Family 1, Â, MSET, CSE, CRO, Safety, FSE, Drug discovery, Cancer, Development, CEO, GLOBE, Pharmaceutical industry, Mindset

Recently, the Company engaged a UK-based Contract Research Organization (CRO), Clerkenwell Health , to prepare for an initial scientific meeting with regulators to discuss the companys initial plans for clinical development.

Key Points: 
  • Recently, the Company engaged a UK-based Contract Research Organization (CRO), Clerkenwell Health , to prepare for an initial scientific meeting with regulators to discuss the companys initial plans for clinical development.
  • At Mindset, we are working diligently to advance MSP-1014 through the regulatory process as quickly as possible.
  • We have selected an expert CRO, Clerkenwell Health, to lead the initial scientific discussions with the regulators in the UK as we start to pull together our clinical plans.
  • Were invigorated by this next step and look forward to providing updates along the way, said James Lanthier, CEO of Mindset.